成人慢性髓性白血病骨髓细胞内IL-1受体拮抗剂的表达及意义

The Significance of Intracellular IL-1ra Expression in the Bone Marrow Cells from Adult Chronic Myelogenous Leukemia

为了研究细胞内白细胞介素 1受体拮抗剂 (intracellularinterleukin 1receptorantagonist,icIL 1ra)在成人慢性髓性白血病 (chronicmyeloidleukemia ,CML)骨髓细胞不同群体细胞内的表达及意义 ,本研究利用 15种不同荧光标记的单克隆抗体 ,将骨髓细胞分成不同的群体 ,通过流式细胞术检测未治的 ,经STI5 71(signaltransductioninhibitor5 71)或其它药物治疗的CML慢性期 (chronicphase,CP)和加速 急变期 (acceleratedorblasticphase ,AP BP)病人及正常人骨髓不同群细胞中icIL 1ra的表达。结果显示 :①IL 1ra表达于CML病人及正常人所有的有核细胞内 ,但各群细胞的表达量不同 ,以粒细胞表达量最高 ,淋巴细胞表达量最低 ;② 17例未治CML病人骨髓总有核细胞、粒细胞、淋巴细胞icIL 1ra平均荧光强度明显低于 8例正常人组 ;③ 13例骨髓幼稚细胞数大于或等于 10 %的CML AP BP病人骨髓总有核细胞、粒细胞及淋巴细胞icIL 1ra平均荧光强度明显低于 4 3例幼稚细胞数小于 5 %或 9例幼稚细胞数为 5 % - 10 %的CML CP病人。结论 :CML病人骨髓总有核细胞与正常人相比icIL 1ra表达降低。icIL 1ra在CML病人骨髓总有核细胞表达量降低可能是CML疾病进展的因素之一。

To estimate intracellular interleukin 1 receptor antagonist (icIL 1ra) expression in the bone marrow cells from adult patients with chronic myelogenous leukemia (CML), flow cytometry (FCM) assay was used for detecting the mean icIL 1ra fluorescence intensity per cell (equivalent to it′s expression level) in different groups of cells from normal and CML patient bone marrows by 15 monoclonal antibodies with different fluorescent marker. The results showed that all of marrow nucleated cells express IL 1ra, but its expression level in granulocytes was the highest and that in lymphocytes was the lowest. The icIL 1ra expression level was significantly lower in nucleated marrow cells, granulocytes and lymphocytes from the marrow of 17 untreated CML patients than that from the marrow of 8 normal. The mean icIL 1ra fluorescence intensity was significantly lower in marrow nucleated cells, granulocytes and lymphocytes in 13 CML patients with marrow blasts ≥10% than that in 43 CML patients with marrow blasts <5% or than that in 9 CML patients with marrow blasts 5%-10%. It was concluded that the lower expression of icIL 1ra in CML marrow nucleated cells might be involved in the evolution of CML.